Intracellular Therapeutics Pipeline
Diverse and Expanding Pipeline of Programs Spanning Discovery and Clinical Development
At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.
Learn more about our proprietary EEV™ Platform.
Information is current as of January 8, 2026, updates are made on a quarterly basis.
Duchenne Muscular Dystrophy (DMD)
To learn more about Duchenne muscular dystrophy, visit our DMD Page.
ENTR-601-44 (Exon 44 Skipping Oligonucleotide)
Preclinical
100%
complete
Phase 1/2
50%
complete
Phase 2/3
0%
complete
ENTR-601-45 (Exon 45 Skipping Oligonucleotide)
Preclinical
100%
complete
Phase 1/2
25%
complete
Phase 2/3
0%
complete
ENTR-601-50 (Exon 50 Skipping Oligonucleotide)
Preclinical
100%
complete
Phase 1/2
0%
complete
Phase 2/3
0%
complete
ENTR-601-51 (Exon 51 Skipping Oligonucleotide)
Preclinical
90%
complete
Phase 1/2
0%
complete
Phase 2/3
0%
complete
Myotonic Dystrophy Type 1 (DM1)
To learn more about Myotonic dystrophy type 1, visit our DM1 Page.
VX-670 (Oligonucleotide) 1
Preclinical
100%
complete
Phase 1/2
50%
complete
Phase 2/3
0%
complete
Inherited Retinal Diseases
ENTR-801: USH2A
Preclinical
85%
complete
Phase 1/2
0%
complete
Phase 2/3
0%
complete
Undisclosed Programs
Preclinical
75%
complete
Phase 1/2
0%
complete
Phase 2/3
0%
complete
Pipeline and Platform Expansion
Undisclosed
Preclinical
65%
complete
Phase 1/2
0%
complete
Phase 2/3
0%
complete
References
-
1.
In collaboration with
